Subsequently, lenvatinib, a multi-kinase inhibitor targeting key receptors including vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) receptors related to tumor angiogenesis, has changed the chemotherapy for HCC [7]. Here, VEGFA is linked to neoplasm.